3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
10
Breast Neoplasms
9
Prostatic Neoplasms
7
Multiple Myeloma
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Leukemia, Myeloid, Acute
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Recurrence
3
Neoplasms, Plasma Cell
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Glioblastoma
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms by Site
2
Mycoses
2
Medication Adherence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia
2
Carcinoma, Transitional Cell
2
COVID-19
2
Adenocarcinoma
2
Uveal Melanoma
1
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Interventions
Gemcitabine
28
pembrolizumab
24
Cisplatin
24
Fluorouracil
11
Leucovorin
10
Oxaliplatin
8
Nivolumab
7
Capecitabine
6
Irinotecan
5
Drug Therapy
5
pemigatinib
4
futibatinib
4
Paclitaxel
4
Carboplatin
4
ivosidenib
3
durvalumab
3
derazantinib
3
Folfox protocol
3
Bevacizumab
3
zanidatamab
2
spartalizumab
2
olutasidenib
2
lenvatinib
2
infigratinib
2
fludarabine
2
budigalimab
2
Trastuzumab
2
Ipilimumab
2
Injections
2
Docetaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Cholangiocarcinoma
×
Standard of Care
×
Clear all
NCT04099888
2023-09-11
RELEASE
PCI Biotech AS
Phase 2
Terminated
41 enrolled
17 charts